RT @uptoTate: DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and w

Social Author Image
https://pbs.twimg.com/profile_images/847812732007133184/hIbnEHt3.jpg
Tweet Author
uptoTate
Social Author Name
Dr. Rachel Tate
Tweet Content
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Links
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh… http://ow.ly/sijt50Lz2GJ
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.